MA49498A - Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant - Google Patents

Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant

Info

Publication number
MA49498A
MA49498A MA049498A MA49498A MA49498A MA 49498 A MA49498 A MA 49498A MA 049498 A MA049498 A MA 049498A MA 49498 A MA49498 A MA 49498A MA 49498 A MA49498 A MA 49498A
Authority
MA
Morocco
Prior art keywords
diethylphenyl
pyrazolo
quinazoline
carboxamide
methoxyphenyl
Prior art date
Application number
MA049498A
Other languages
English (en)
Inventor
Marina Caldarelli
Ilaria Candiani
Matteo D'anello
Germano D'arasmo
Massimo Zampieri
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of MA49498A publication Critical patent/MA49498A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA049498A 2017-06-29 2018-06-28 Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant MA49498A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305826 2017-06-29

Publications (1)

Publication Number Publication Date
MA49498A true MA49498A (fr) 2021-05-26

Family

ID=59313166

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049498A MA49498A (fr) 2017-06-29 2018-06-28 Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant

Country Status (19)

Country Link
US (3) US11160806B2 (fr)
EP (1) EP3645535B1 (fr)
JP (1) JP7141416B2 (fr)
KR (1) KR102609333B1 (fr)
CN (1) CN110896636B (fr)
AR (1) AR112040A1 (fr)
AU (1) AU2018293729B9 (fr)
CA (1) CA3068357C (fr)
CL (1) CL2019003848A1 (fr)
EA (1) EA039764B1 (fr)
ES (1) ES2900048T3 (fr)
IL (1) IL271628B2 (fr)
MA (1) MA49498A (fr)
PL (1) PL3645535T3 (fr)
PY (1) PY1850855A (fr)
SG (1) SG11201912651WA (fr)
TW (1) TWI750393B (fr)
UY (1) UY37778A (fr)
WO (1) WO2019002454A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002962A1 (fr) 2023-06-30 2025-01-02 Nerviano Medical Sciences S.R.L. Utilisation d'un inhibiteur de mps1 pour le traitement du carcinome hépatocellulaire
WO2025021587A1 (fr) 2023-07-21 2025-01-30 Nerviano Medical Sciences S.R.L. Combinaison d'un inhibiteur de mps1 et d'inhibiteurs de point de contrôle immunitaire, utilisations et compositions pharmaceutiques associées

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020703B9 (ru) * 2008-06-26 2015-12-30 Ле Лаборатуар Сервье Пиразолохиназолины

Also Published As

Publication number Publication date
CN110896636B (zh) 2022-07-19
US11160806B2 (en) 2021-11-02
EP3645535B1 (fr) 2021-09-08
PY1850855A (es) 2019-04-01
WO2019002454A1 (fr) 2019-01-03
AU2018293729B9 (en) 2022-07-14
CL2019003848A1 (es) 2020-07-10
IL271628A (en) 2020-02-27
AU2018293729A1 (en) 2020-01-23
BR112019027924A2 (pt) 2020-08-18
TWI750393B (zh) 2021-12-21
AR112040A1 (es) 2019-09-11
CA3068357A1 (fr) 2019-01-03
ES2900048T3 (es) 2022-03-15
EP3645535A1 (fr) 2020-05-06
CA3068357C (fr) 2022-04-19
IL271628B1 (en) 2023-03-01
TW201904971A (zh) 2019-02-01
PL3645535T3 (pl) 2022-03-21
AU2018293729B2 (en) 2022-03-10
UY37778A (es) 2019-01-31
CN110896636A (zh) 2020-03-20
EA202090115A1 (ru) 2020-05-25
US20220016122A1 (en) 2022-01-20
KR102609333B1 (ko) 2023-12-01
US20200246339A1 (en) 2020-08-06
JP7141416B2 (ja) 2022-09-22
JP2020525477A (ja) 2020-08-27
IL271628B2 (en) 2023-07-01
SG11201912651WA (en) 2020-01-30
KR20200020905A (ko) 2020-02-26
US20240350501A1 (en) 2024-10-24
EA039764B1 (ru) 2022-03-11

Similar Documents

Publication Publication Date Title
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
EA201990657A1 (ru) Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
MX2018002017A (es) Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
WO2018045276A8 (fr) Stimulateurs sgc bicycliques fusionnés
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
IL281924A (en) New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
WO2014027975A3 (fr) Nouvelles formulations pharmaceutiques administrées par voie orale
EP3250572A4 (fr) Composés d'imidazo[1,2-a]pyridin-2-ylamine substitués, compositions pharmaceutiques et leurs méthodes d'utilisation
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA201591904A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
WO2016010869A3 (fr) Composés de quinoléine fusionnés utilisés comme inhibiteurs de la voie de signalisation pi3k/mtor
WO2014027981A3 (fr) Formulations de comprimés effervescents de dapoxétine et d'un inhibiteur de pde5
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
MA49498A (fr) Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant
PH12014502407B1 (en) New alfentanil composition for the treatment of acute pain
MX2016017315A (es) Formas de dosificacion farmaceutica.
WO2014027982A3 (fr) Nouvelles formulations de sachets effervescents de dapoxétine et d'un inhibiteur de pde5
AR104315A1 (es) Compuestos de butanamida, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende, su uso para prepararla, y combinación y mezcla que lo comprenden